Market Signal Briefing

Darius Baruo
Oct 17, 2025 21:19

Injective price trades at $8.41 near technical support after reaching record transaction milestone, with Bitcoin's $110K breakthrough providing market-wide momentum for recovery.

Quick Take
• INJ trading at $8.41 (down 2.0% in 24h)
• Record transaction milestone achieved signals growing network adoption
• Price testing critical lower Bollinger Band support at $7.55
• Bitcoin's surge past $110,000 lifting broader crypto sentiment

Market Events Driving Injective Price Movement
Injective Protocol's announcement of surpassing a significant transaction milestone on October 15 has emerged as the primary bullish catalyst for INJ price action this week. The achievement indicates accelerating network activity and adoption, contributing to a 3% price increase following the announcement. This fundamental development demonstrates the protocol's growing utility in the decentralized finance ecosystem.

Bitcoin's breakthrough past $110,000 on October 14 created a positive ripple effect across the cryptocurrency market, with INJ benefiting from the broader altcoin rally that delivered a 5% price boost. The milestone reinforced institutional confidence in digital assets and provided crucial momentum for risk-on positioning in crypto markets.

The Federal Reserve's decision to maintain interest rates on October 13, citing ongoing inflation concerns, had a neutral impact on INJ price. While the decision avoided additional pressure on risk assets, it also limited the potential for aggressive capital rotation into cryptocurrencies.

INJ Technical Analysis: Testing Critical Support Zone
Price Action Context
INJ price currently trades significantly below all major moving averages, with the token positioned at $8.41 compared to the 20-day SMA at $11.14 and 50-day SMA at $12.40. The 24-hour trading range of $7.77 to $8.75 highlights the ongoing consolidation near technical support levels. Injective technical analysis reveals the price is testing the lower Bollinger Band at $7.55, representing a critical juncture for near-term direction.

Trading volume on Binance spot reached $10.87 million in the past 24 hours, indicating moderate institutional interest despite the price decline. The volume profile suggests accumulation near current levels rather than panic selling.

Key Technical Indicators
The RSI reading of 31.45 places INJ in neutral territory with room for recovery without reaching oversold conditions. The MACD histogram at -0.2825 confirms bearish momentum, though the narrowing gap between MACD and signal lines suggests potential stabilization.

Bollinger Bands positioning shows INJ at 0.1197 %B, indicating the price sits very close to the lower band support. This technical setup often precedes either a bounce or a significant breakdown, making the next 48 hours critical for direction.

Critical Price Levels for Injective Traders
Immediate Levels (24-48 hours)
• Resistance: $9.08 (7-day moving average confluence)
• Support: $7.55 (lower Bollinger Band and psychological level)

Breakout/Breakdown Scenarios
A break below $7.55 support could trigger selling toward the strong support zone at $2.74, representing significant downside risk. Conversely, reclaiming the $9.08 level would signal potential recovery toward the $11.14 resistance at the 20-day moving average.

INJ Correlation Analysis
Injective demonstrates strong correlation with Bitcoin's price movements, as evidenced by the 5% rally following BTC's $110,000 breakthrough. This correlation suggests INJ price will likely follow Bitcoin's lead in the near term, making BTC technical levels crucial for INJ traders.

Traditional market correlations remain muted, with the Federal Reserve's rate decision having minimal direct impact on INJ price action. The focus remains on crypto-specific catalysts and Bitcoin's momentum.

Trading Outlook: Injective Near-Term Prospects
Bullish Case
The transaction milestone achievement provides fundamental support for higher valuations, while the oversold technical condition near lower Bollinger Band support creates potential for a relief rally. A sustained Bitcoin rally above $110,000 could drive INJ toward the $11.14 resistance level.

Bearish Case
Failure to hold $7.55 support combined with Bitcoin weakness could trigger accelerated selling toward the $2.74 major support zone. The bearish MACD configuration suggests downside momentum remains intact.

Risk Management
Conservative traders should consider stop-losses below $7.50 to limit downside exposure. Given the Average True Range of $1.28, position sizing should account for potential 15-20% daily volatility swings.

Image source: Shutterstock

inj price analysis
inj price prediction

Since making its debut ahead of President Trump's inauguration in January, it has been a steady slide for the TRUMP token.

Iris Coleman
Oct 17, 2025 21:30

Algorand trades at $0.18 after Bitcoin's 5% weekly decline pressures altcoins, with ALGO price testing critical technical support levels amid mixed ecosystem signals.

Quick Take
• ALGO trading at $0.18 (down 3.1% in 24h)
• Bitcoin's weekly decline creating selling pressure across altcoins
• Price testing lower Bollinger Band support at current levels
• Technical indicators showing oversold conditions developing

Market Events Driving Algorand Price Movement
Bitcoin's approximately 5% decline over the past week has created a cascading effect across the broader cryptocurrency market, with ALGO price following the broader risk-off sentiment. The leading cryptocurrency closed at $108,186 on October 16, marking a significant weekly pullback that has weighed heavily on altcoin performance.

Despite this macro headwind, Algorand's ecosystem fundamentals showed notable strength with monthly active users surging 34% to 1.34 million in Q3 2025. This growth was driven by increased dApp adoption and initiatives like Coinbase Quests, though governance changes including the removal of staking features have sparked some community skepticism.

The technical momentum indicators from earlier this week suggested potential targets in the $0.26-$0.29 resistance zone, representing 13-26% upside potential. However, Bitcoin's renewed weakness has temporarily overshadowed these positive technical setups, with ALGO price now testing critical support levels.

ALGO Technical Analysis: Testing Lower Band Support
Price Action Context
ALGO price currently sits at the lower Bollinger Band at $0.18, representing a critical technical juncture. The cryptocurrency is trading below all major moving averages, with the 7-day SMA at $0.19 providing immediate overhead resistance. The 20-day, 50-day, and 200-day SMAs all converging around $0.21-$0.22 suggests this level will act as significant resistance on any recovery attempt.

Trading volume on Binance spot market reached $9.67 million in the past 24 hours, indicating moderate institutional interest despite the price decline. The current positioning below key moving averages reflects the broader crypto market's correlation with Bitcoin's recent weakness.

Key Technical Indicators
The RSI has dropped to 37.06, approaching oversold territory and suggesting potential for a technical bounce if Bitcoin stabilizes. The MACD remains in bearish territory at -0.0097, though the histogram at -0.0022 shows momentum may be slowing.

Algorand technical analysis reveals the Stochastic oscillator at 60.46/%K and 66.36/%D, indicating the market isn't deeply oversold yet, which could allow for further downside if Bitcoin continues declining.

Critical Price Levels for Algorand Traders
Immediate Levels (24-48 hours)
• Resistance: $0.19 (7-day moving average and previous support turned resistance)
• Support: $0.17 (24-hour low and psychological round number)

Breakout/Breakdown Scenarios
A break below $0.17 would target the strong support zone at $0.10, representing the yearly low area. Conversely, a reclaim of $0.19 could spark a relief rally toward $0.21 where multiple moving averages converge.

ALGO Correlation Analysis
Bitcoin correlation remains strong, with ALGO price movements closely tracking the broader crypto market leader's direction. The 5% Bitcoin decline this week directly contributed to ALGO's 3.1% daily loss and broader weekly weakness.

Traditional markets haven't shown significant correlation recently, with crypto-specific factors and Bitcoin's performance being the primary drivers. Among DeFi and smart contract platforms, Algorand is performing in line with sector peers during this risk-off period.

Trading Outlook: Algorand Near-Term Prospects
Bullish Case
A Bitcoin stabilization above $108,000 could allow ALGO price to bounce from current lower Bollinger Band support. The RSI approaching oversold levels creates conditions for a technical rebound toward $0.21-$0.22 resistance cluster.

Bearish Case
Continued Bitcoin weakness below $108,000 would likely pressure ALGO toward the $0.17 support level and potentially the strong support zone at $0.10. The MACD remaining in negative territory suggests downside momentum could persist.

Risk Management
Traders should consider stop-losses below $0.17 for long positions, with the daily ATR of $0.02 providing guidance for position sizing. The current volatility environment suggests keeping position sizes modest until Bitcoin establishes a clearer directional bias.

Image source: Shutterstock

algo price analysis
algo price prediction

The ongoing competition between Binance and Coinbase has intensified after Binance founder Changpeng Zhao (CZ) publicly called on Coinbase to list more BNB Chain projects. The statement comes shortly after Coinbase added BNB to its official listing roadmap, signaling tentative engagement with the Binance ecosystem.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

ETF issuer Volatility Shares recently filed with the US SEC to launch highly leveraged XRP ETFs, alongside other cryptocurrencies and stocks. Particularly, Volatility Shares has decided to file for a 5× leveraged XRP ETF, a move that caught many traders and analysts off guard. 

Discussions have intensified among investors following the filing, as it stands out as one of the boldest attempts yet in the crypto ETF world, especially since the SEC has yet to even approve any 3× leveraged crypto products.

Volatility Shares’ Expansive ETF Filing
According to filings, Volatility Shares is planning to launch both 3x and 5x leveraged ETFs tracking the price of XRP alongside other major cryptocurrencies such as Solana, Bitcoin, and Ethereum. The ETF proposed by Volatility Shares will use futures, swaps and options to achieve a magnified daily performance exposure.

The move signals that the issuer is prepared to push the limits of what the US Securities and Exchange Commission (SEC) might tolerate, creating a major twist in the increasing popularity of investment funds linked to digital assets. If approved, the earliest activation date for these leveraged ETFs is December 29, 2025.

Market analysts were taken aback, with the filing seeing mixed reactions on social media platforms. ETF expert Henry Jim announced the scope of Volatility Shares’ filing on the social-media platform X. In his post, he exclaimed, “Sonic BOOOM! — 27 leveraged 3× and 5× single-stock ETFs filed by Volatility Shares!

His list of the Volatility Shares’ filing included tech heavyweights such as AMD, Amazon, Google, Nvidia, Palantir, and Tesla, alongside crypto-focused funds for Bitcoin, Ethereum, Solana, and XRP, and crypto-related stocks such as crypto exchange Coinbase and Bitcoin treasury firm Strategy. The extensive slate indicates that Volatility Shares is attempting to corner both the equity and crypto leverage markets.

Bloomberg ETF analyst Eric Balchunas also expressed astonishment regarding the filings. Balchunas added that the firm could be making an option on a long-term government shutdown, since if there’s no SEC action in 75 days, they can launch.

Risks Of Highly Leveraged ETFs
Volatility Shares’ proposal for a 5× leveraged ETF comes in the aftermath of the most severe crypto market liquidations, where over $19 billion was wiped out across crypto exchanges in a single weekend. Data from derivatives platforms showed that the majority of those liquidations came from highly leveraged positions. 

Therefore, these proposed ETFs are a double-edged sword in terms of contributions to the crypto market. For one, it could provide an avenue for more institutional funds into XRP and other cryptocurrencies. If successful, these ETFs could also set a precedent for future high-risk crypto products in the US market. 

On the other hand, the risk is also magnified. If XRP falls by 2% in a day, the 5× leveraged fund will lose 10%, and that’s just in one day.

XRP trading at $2.2 on the 1D chart | Source: XRPUSDT on Tradingview.com
Featured image from Adobe Stock, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Dogecoin's next inflection could arrive as soon as October 22–23, according to crypto analyst VisionPulsed, who argues that the memecoin's multi-month rising channel will either confirm with a higher low in the $0.16–$0.18 region or give way to another full “round trip” into year-end.

XRP has continued to spark fears among investors as whales are increasingly dumping their tokens amid ongoing market uncertainty. 

On Friday, October 17, on-chain tracking platform Whale Alert shared data showing over 106 million XRP being transferred in a move that appears to be an attempt to sell.

The tracker spotted two large, consecutive transactions — 53,399,340 XRP and 53,356,907 XRP — being moved between unknown wallets and Coinbase.

HOT Stories

While both transfers are collectively worth over $242 million, commentators have suggested that whales may be strategically dumping their holdings to hedge against further losses.

Although the exact nature of the transactions was not disclosed, they signal mounting sell pressure, which could weigh heavily on price performance and trigger deeper corrections.

While some commentators have speculated that one of the transactions might be an OTC (over-the-counter) transfer occurring outside of a crypto exchange, many others have expressed skepticism, believing that both transfers were influenced by the prevailing negative market sentiment.

 XRP to retest $1?With the XRP market structure appearing increasingly weak and on the verge of a total collapse, there are few, if any, support levels left between current prices and the psychological threshold of $1.00.

This suggests that XRP could retest the $1 level in the near term if market momentum does not turn bullish soon. Beyond the increasing selling activity observed in the market, whales have continued to liquidate large positions, putting overall liquidity under significant pressure.

However, despite the consistent price declines, analysts remain optimistic about XRP’s long-term prospects. Analysts attribute this optimism to Ripple’s recent developments, highlighting reasons why investors should remain bullish on XRP despite the distressed market conditions.

As Ripple continues to aggressively expand its global presence — through major developments such as the launch of its RLUSD stablecoin in Africa and its custody partnership with Absa Bank — the demand for XRP is expected to rise to new heights.

These initiatives, which strengthen XRP’s utility in cross-border payments, are anticipated to support a longer-term recovery for the asset despite the ongoing market bloodbath.

Andreessen Horowitz's crypto arm has made a $50 million investment in Jito, a Solana-based liquid staking protocol. The deal, the largest ever for Jito, strengthens long-term alignment between the venture firm and the Solana ecosystem.

Wave 4 pause hints at one final leg down before a major bullish reversal for XRP.

NEW YORK--(BUSINESS WIRE)--FuboTV Inc. (d/b/a Fubo) (NYSE: FUBO), the leading sports-first live TV streaming platform, today announced that on October 16, 2025, the Compensation Committee of Fubo’s Board of Directors granted restricted stock unit awards covering an aggregate of 74,320 shares of its common stock to 12 new employees to induce them to join Fubo. The awards were granted under Fubo’s 2025 Employment Inducement Equity Incentive Plan, and vest annually over a four-year period following their grant, subject to continued employment. The awards were granted as employment inducement awards pursuant to the New York Stock Exchange rules.

About Fubo

With a global mission to aggregate the best in TV, including premium sports, news and entertainment content, through a single app, FuboTV Inc. (d/b/a Fubo) (NYSE: FUBO) aims to transcend the industry’s current TV model. Ranked among The Americas’ Fastest-Growing Companies 2025 by the Financial Times, the company operates Fubo in the U.S., Canada and Spain and Molotov in France.

In the U.S., Fubo is a sports-first cable TV replacement product aggregating more than 400 live sports, news and entertainment networks and is the only live TV streaming platform with every English-language Nielsen-rated sports channel (source: Nielsen Total Viewers, 2024). Leveraging Fubo’s proprietary data and technology platform optimized for live TV and sports viewership, subscribers can engage with the content they are watching through an intuitive and personalized streaming experience. Fubo has continuously pushed the boundaries of live TV streaming, and was the first virtual MVPD to launch 4K streaming, MultiView and personalized game alerts.

Learn more at https://fubo.tv

Q3: 2025-10-17 Earnings SummaryEPS of $0.63 beats by $0.03

 |

Revenue of

$1.93B

(6.99% Y/Y)

misses by $6.06M

Regions Financial Corporation (NYSE:RF) Q3 2025 Earnings Call October 17, 2025 10:00 AM EDT

Company Participants

Dana Nolan - EVP & Head of Investor Relations
John Turner - President, CEO & Chairman
David Turner - Senior EVP & CFO

Conference Call Participants

Kenneth Usdin - Bernstein Autonomous LLP
Robert Siefers - Piper Sandler & Co., Research Division
Steven Alexopoulos - TD Cowen, Research Division
John Pancari - Evercore ISI Institutional Equities, Research Division
David Rochester - Cantor Fitzgerald & Co., Research Division
Gerard Cassidy - RBC Capital Markets, Research Division
Ebrahim Poonawala - BofA Securities, Research Division
Christopher McGratty - Keefe, Bruyette, & Woods, Inc., Research Division
Betsy Graseck - Morgan Stanley, Research Division
Christopher Spahr - Wells Fargo Securities, LLC, Research Division

Presentation

Operator

Good morning, and welcome to the Regions Financial Corporation's quarterly earnings call. My name is Chris, and I will be your operator for today's call. [Operator Instructions]

I will now turn the call over to Dana Nolan to begin.

Dana Nolan
EVP & Head of Investor Relations

Thank you, Chris. Welcome to Regions' Third Quarter earnings call. John and David will provide high-level commentary regarding our results. Earnings documents, which include our forward-looking statement disclaimer and non-GAAP reconciliations are available in the Investor Relations section of our website. These disclosures cover our presentation materials, today's prepared remarks and Q&A.

I will now turn the call over to John.

John Turner
President, CEO & Chairman

Thank you, Dana, and good morning, everyone. We appreciate you joining our call today. Earlier this morning, we reported strong quarterly earnings of $548 million, resulting in earnings per share of $0.61. On an adjusted basis, earnings were $561 million or $0.63 per share. We delivered adjusted pretax pre-provision income of $830 million, a 4% increase year-over-year, and we generated a strong return on tangible common equity of 19%.

We

Recommended For You

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a complex epithelial-driven inflammatory condition. TEZSPIRE is the first and only biologic that targets thymic stromal lymphopoietin (TSLP) to be approved for CRSwNP.

The approval by the US Food and Drug Administration (FDA) was based on efficacy and safety data from the WAYPOINT Phase III trial, which were presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress and simultaneously published in The New England Journal of Medicine.1,2 In the trial, TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp severity, and showed near-elimination of the need for surgery and significant reduction in systemic corticosteroid use vs. placebo.1,2

Dr. Joseph Han, Vice Chair of Department of Otolaryngology - Head and Neck Surgery, Old Dominion University, US, and co-primary investigator in the WAYPOINT trial, said: “Over 320 million lives globally are disrupted by chronic rhinosinusitis with nasal polyps. The FDA approval of TEZSPIRE brings forward a new treatment option that has demonstrated rapid and sustained symptom improvement, nearly eliminating the need for future surgeries and significantly reducing systemic steroid use. By targeting TSLP at the top of the inflammatory cascade, TEZSPIRE offers a novel option for patients who continue to endure the disruption of this disease despite available treatments.”

Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA), said: “Chronic rhinosinusitis with nasal polyps is a persistent and often-overlooked disease that can significantly impact daily life, robbing patients of their ability to breathe without congestion and full sense of smell. This approval introduces an innovative treatment option for patients with the potential to help address the ongoing cycle of debilitating symptoms, surgeries and systemic steroid use.”

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca said: “Today’s approval of TEZSPIRE in chronic rhinosinusitis with nasal polyps expands the reach of this innovative treatment option to patients living with an epithelial-driven inflammatory disease beyond severe asthma. Building on the widespread, established use of TEZSPIRE in severe asthma, this exciting milestone now reinforces its unique mechanism of action across both the upper and lower airways and reflects our commitment to transforming care for patients who face the daily burden of chronic respiratory and immune-mediated diseases.”

CRSwNP affects up to approximately 320 million people worldwide and is a complex epithelial-driven inflammatory condition characterized by persistent inflammation and benign polyp growths within the nasal cavity. People living with CRSwNP commonly experience airflow obstruction and symptoms including congestion and an impaired sense of smell.3-7 For many patients, current therapies such as systemic and intranasal corticosteroids and repeated sinus surgeries do not offer lasting relief.4

The safety profile and tolerability of TEZSPIRE in the WAYPOINT trial was generally consistent with the known profile of the medicine.1 The most frequently reported adverse events in the trial were COVID-19, nasopharyngitis and upper respiratory tract infection.1

The Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion for the approval of TEZSPIRE in the EU for treatment of CRSwNP.8 Regulatory applications are currently under review in the EU, China, Japan and several other countries.

TEZSPIRE is currently approved for the treatment of severe asthma in the US, EU, Japan and more than 60 countries across the globe.9-11

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Acute Asthma Symptoms or Deteriorating Disease

TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Live Attenuated Vaccines

The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 3%) are:

Asthma: pharyngitis, arthralgia, and back pain.

Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia

USE IN SPECIFIC POPULATIONS

There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATION

TEZSPIRE is indicated for:

the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus

the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)

Please see accompanying full Prescribing Information, including Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products.

Notes

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP (nasal polyps))

CRSwNP is a complex inflammatory disorder, characterized by persistent inflammation of the nasal mucosa accompanied by benign growths, called nasal polyps.3,4 Nasal polyps can block nasal passages and lead to breathing problems, difficulty in sense of smell, nasal discharge, facial pain, sleep disturbance and other adverse effects on quality of life. 5-7

Epithelial dysfunction and inflammation are important characteristics of chronic rhinosinusitis and impede the ability of the epithelium to act as a physical and immunological barrier against the external environment.12,13 Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that has been implicated in shared pathophysiological processes underlying severe asthma and CRSwNP.12,13

Current treatments for CRSwNP include intranasal and/or systemic corticosteroids, surgery and biologics.4,7,14-19

Phase III WAYPOINT trial

WAYPOINT was a double-blind, multi-center, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with uncontrolled CRSwNP.1,2,20 Participants received tezepelumab or placebo, administered via subcutaneous injection. The trial also included a post-treatment follow-up period of 12-24 weeks for participants who completed the 52-week treatment period.1,20

The co-primary endpoints of the trial, were change from baseline in total nasal polyp size, measured by the endoscopic total Nasal Polyp Score, and change from baseline in bi-weekly mean nasal congestion, measured by the participant reported Nasal Congestion Score evaluated as part of the daily Nasal Polyposis Symptom Diary.1,20 Key secondary endpoints included loss of smell; improvement in disease specific health-related quality of life as measured by Sino-Nasal Outcome Test (SNOT-22) score; Lund-Mackay score; time to surgery decision and/or systemic corticosteroids for nasal polyposis; time to nasal polyposis surgery decision; time to systemic corticosteroids for nasal polyposis; Nasal Polyposis Symptom Diary total symptom score and, in the population with co-morbid asthma, pre-bronchodilator FEV1 at Week 52.1,20

TEZSPIRE

TEZSPIRE (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other types of epithelial inflammation associated with severe asthma, CRSwNP and other inflammatory diseases.12,13

TSLP is released by the epithelium in response to environmental triggers (including allergens, viruses and other airborne particles) associated with asthma, CRSwNP, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other diseases.13,21 Across these disease states, the expression of TSLP is increased and correlates with disease severity.7,11

TEZSPIRE is approved as a single-use pre-filled syringe and auto-injector for self-administration in the US and EU.9-11 Since 2021, over 100,000 patients have been treated with TEZSPIRE for severe asthma.22

Beyond CRSwNP, TEZSPIRE is also being explored in Phase III trials in COPD and EoE.23,24 In October 2021, TEZSPIRE was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of EoE.25

Amgen Collaboration

The 2012 Collaboration Agreement between Amgen and AstraZeneca has been amended and updated over time. For TEZSPIRE, both companies continue to share costs and profits equally after payment by AstraZeneca of a mid single-digit inventor royalty to Amgen. AstraZeneca continues to lead development and Amgen continues to lead manufacturing. All aspects of the collaboration are under the oversight of joint governing bodies. Under the agreement, Amgen and AstraZeneca jointly commercialize TEZSPIRE in the US. Amgen records product sales in the US, with AZ recording its share of US profits as Collaboration Revenue. Outside of the US, AstraZeneca records product sales, with Amgen recording profit share as Other/Collaboration revenue.

AstraZeneca in Respiratory & Immunology

Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals is a key disease area and growth driver to the Company.

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow the Company on social media @AstraZeneca.

References

Lipworth BJ, Han JK, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178-1188. DOI: 10.1056/NEJMoa2414482.

Lipworth BJ, Han JK, et al. Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps: results from the Phase 3 WAYPOINT Study. [Late breaking oral presentation]. Presented at the American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress 2025 (28 February – 03 March).

Bachert C, et al. Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621-628.

Del Toro E, Portela J. Nasal Polyps. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK560746/. Accessed October 2025.

Stevens WW, et al. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016; 4(4):565-572.

Abdalla S, et al. Prevalence of sinonasal outcome test (SNOT-22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit. Clin Otolaryngol. 2012;37(4):276-282.

Chen S, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897-1911.

AstraZeneca news release. TEZSPIRE recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps. Available at: https://www.astrazeneca.com/media-centre/press-releases/2025/TEZSPIRE-recommended-for-approval-in-eu-for-crswnp.html. Accessed October 2025.

TEZSPIRE (tezepelumab) US prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s003lbl.pdf. Accessed October 2025.

TEZSPIRE (tezepelumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/TEZSPIRE-epar-product-information_en.pdf. Accessed October 2025.

AstraZeneca news release. TEZSPIRE approved in Japan for the treatment of severe asthma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/TEZSPIRE-approved-in-japan-for-severe-asthma.html. Accessed October 2025.

Corren J, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936-946.

Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front Immunol. 2018;9:1595.

Xolair (omalizumab) Summary of Product Characteristics; Available at: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf. Accessed October 2025.

Xolair (omalizumab) US prescribing information; Available at: https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed: October 2025.

Nucala (mepolizumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf. Accessed October 2025.

Nucala (mepolizumab) US prescribing information; Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761122s006,125526s018lbl.pdf. Accessed October 2025.

Dupixent (dupilumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed October 2025.

Dupixent (dupilumab) US prescribing information; Available at: https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed October 2025.

Clinicaltrials.gov. Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). Available at: https://clinicaltrials.gov/ct2/show/NCT04851964. Accessed October 2025.

Zhang M, et al. Hypoxia induces the production of epithelial-derived cytokines in eosinophilic chronic rhinosinusitis with nasal polyps. Int Immunopharmacol. 2023;121:110559.

AstraZeneca Data on file. 2025. REF-278452.

Clinicaltrials.gov. Tezepelumab COPD Exacerbation Study (COURSE) [Online]. Available at: https://clinicaltrials.gov/ct2/show/NCT04039113. Accessed October 2025.

Clinicaltrials.gov. Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING). Available at: https://clinicaltrials.gov/study/NCT05583227. Accessed October 2025.

AstraZeneca news release. Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html. Accessed October 2025.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Agrees to Board Size Reduction and Certain Director Compensation Limitations; Star Equity Withdraws Nominations

October 17, 2025 16:20 ET

 | Source:

Gyrodyne, LLC

ST. JAMES, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Gyrodyne, LLC (Nasdaq: GYRO), an owner and manager of a diversified portfolio of real estate properties (“Gyrodyne”), today announced that it has entered into an agreement (the “Agreement”) with Star Equity Fund, LP (“Star Equity Fund”), under which Star Equity Fund has withdrawn its slate of nominees for election at the 2025 annual shareholders meeting, and Gyrodyne will reduce the size of its board from five to four directors, freeze director compensation and limit the aggregate fee paid to the Chairman to $65,000. In connection with the reduction in board size, Richard Smith will be the sole nominee standing for election at the 2025 annual shareholders meeting.

Star Equity has also agreed to certain customary standstill provisions. The full agreement with Star Equity will be filed in a Current Report on Form 8-K with the Securities and Exchange Commission.

The agreement with Star Equity Fund reflects Gyrodyne’s continued commitment to constructive engagement with shareholders as part of its ongoing efforts to strengthen governance, enhance transparency and drive long-term value creation for all shareholders.

Gary Fitlin, Gyrodyne’s President and Chief Executive Officer, stated that “We appreciate the thoughtful input from Star Equity and our broader shareholder base. Their perspectives have strengthened our efforts as we work toward completing the sale of our properties and delivering maximum value to our shareholders.”

Jeff Eberwein, manager of Star Equity Fund, added that “Following the most recent constructive discussions with the company, we are pleased to have worked collaboratively with the Board to enhance governance and further align with shareholders’ interests”.

Nader Salour, Chairman of Gyrodyne’s Nominating Committee, also added: “On behalf of the entire company and Board of Directors, I want to express our deep gratitude to Paul Lamb for his extraordinary 28 years of service to Gyrodyne. His steady leadership and strategic vision have been instrumental in guiding the company through periods of tremendous challenge and transformation. Paul Lamb leaves behind a lasting legacy of integrity and a steadfast commitment to our stakeholders. While he will not be standing for re-election at the upcoming shareholders’ meeting, as a significant shareholder he will continue to be an important voice and valued supporter of the company’s long-term success. We thank him for his many contributions and wish him the very best in the years ahead.”

About Gyrodyne, LLC

Gyrodyne, LLC owns and manages a diversified portfolio of real estate properties comprising office, industrial and service-oriented properties in the New York metropolitan area. The Company owns a 63 acre site approximately 50 miles east of New York City on the north shore of Long Island, which includes industrial and office buildings and undeveloped property, and a medical office park in Cortlandt Manor, New York, both of which are the subject of plans to seek value-enhancing entitlements. The Company’s common shares are traded on the NASDAQ Stock Market under the symbol GYRO. Additional information about the Company may be found on its web site at www.gyrodyne.com.

Forward-Looking Statements

The statements made in this press release that are not historical facts constitute "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995, and Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, both as amended, which can be identified by the use of forward-looking terminology such as "may," "will," "anticipates," "expects," "projects," "estimates," "believes," "seeks," "could," "should," or "continue," the negative thereof, other variations or comparable terminology as well as statements regarding the evaluation of strategic alternatives. Important factors, including certain risks and uncertainties, with respect to such forward-looking statements that could cause actual results to differ materially from those reflected in such forward-looking statements include, but are not limited to, risks and uncertainties generally relating to our efforts to enhance the values of our remaining properties and seek the orderly, strategic sale of such properties as soon as reasonably practicable, risks associated with the Article 78 Proceeding against the Company and any other litigation that may develop in connection with our efforts to enhance the value of and sell our properties, risks relating to our national marketing campaign led by JLL for the sale of our Flowerfield and Cortlandt Manor properties, risks associated with our purchase and sale agreement with B2K (and future purchase and sale agreements for our remaining properties that may be contingent on years-long regulatory contingencies) in light of our financial condition, community activism risk, proxy contests and other actions of activist shareholders, regulatory enforcement risk, risks inherent in the real estate markets of Suffolk and Westchester Counties in New York, the potential residual effects of the COVID-19 pandemic, lingering risks relating to the 2023 banking crisis and closure of two major banks (including one with whom we indirectly had a mortgage loan which the FDIC transferred in December 2023 to a new holder following the banks closure), ongoing inflation risk, ongoing interest rate uncertainty, recession uncertainty and supply chain constraints or disruptions, and other risks detailed from time to time in Gyrodyne’s SEC reports.

Contact:

Gary Fitlin
Chief Executive Officer
Gyrodyne, LLC
Phone: (631) 584-5400
[email protected]
https://www.gyrodyne.com  

Doug Clinton, Deepwater Asset Management, joins 'Closing Bell' to discuss the recent move in Apple's stock ahead of earnings season, why capital expenditure expectations are too low for these two companies and much more.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in LLY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Presentation on Tuesday, October 21st at 9:00 am PT
October 17, 2025 4:27 PM EDT | Source: LD Micro
White Plains, New York--(Newsfile Corp. - October 17, 2025) - Sky Harbour Group Corporation (NYSE: SKYH) and LD Micro announced today that Sky Harbour will be presenting at the 19th annual Main Event on Tuesday, October 21st at 9:00 am PT at the Hotel del Coronado in San Diego, California. Andreas Frank, Assistant Treasurer will be giving the presentation.

"The Main Event is a culmination of over 25 years of hard work and passion for small company investing. There is no organization on planet Earth that cares more about small companies succeeding than LD. To be able to connect with our community in one of the most beautiful settings imaginable brings me considerable joy. We look forward to welcoming all of our patrons and ensuring that they have a wonderful time," stated Chris Lahiji, Founder of LD Micro.

Sky Harbour will also participate in a series of 1x1 investor meetings at the conference. For more information and to register for available meeting slots please visit www.ldmicro.com.

Event: LD Micro Main Event XIX
Date: Tuesday, October 21st
Time: 9:00 am

Register to watch the virtual presentation here.

Summary of LD Micro Main Event XIX

The 2025 LD Micro Main Event XIX will run from October 19th to the 21st at the Hotel del Coronado in San Diego, California.

The first day will consist of registration, keynote speakers, and some gorgeous views of the Pacific. It will be followed by two full days of company presentations and one-on-one investor meetings concluded with a closing reception.

This three-day event will feature around 120 companies, presenting in half-hour increments, and attending private meetings with investors.

About Sky Harbour Group Corporation

Sky Harbour Group Corporation is an aviation infrastructure company developing the first nationwide network of Home-Basing campuses for business aircraft. The company develops, leases, and manages general aviation hangar campuses across the United States. Sky Harbour's Home-Basing offering aims to provide private and corporate residents with the best physical infrastructure in business aviation, coupled with dedicated service, tailored specifically to based aircraft, offering the shortest time to wheels-up in business aviation. To learn more, visit www.skyharbour.group.

About LD Micro

LD Micro is dedicated to being the definitive resource in the small-cap space. From its industry-recognized index and robust data to hosting some of the most influential events each year, LD Micro's mission is to provide unparalleled access and insight for those seeking the next generation of great companies.

To learn more about LD Micro, visit:
http://www.ldmicro.com

To learn more about Freedom US Markets LLC, visit:
https://www.freedomcapmkts.com/

To present or register, please contact [email protected].

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270917

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. (NYSE: FCX) resulting from allegations that Freeport may have issued materially misleading business information to the investing public.

So What: If you purchased Freeport securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=45553 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 24, 2025, Freeport issued a press release entitled "Freeport Provides Update on PT Freeport Indonesia Operations." It stated that Freeport "announced today an update on the status of the previously reported mud rush incident at the Grasberg Block Cave mine (GBC) in Indonesia. On September 20, 2025, PT Freeport Indonesia (PTFI) located two team members who were regrettably fatally injured in the September 8th incident."

On this news, Freeport stock fell by 16.95% on September 24, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) between December 15, 2021 and September 16, 2025, both dates inclusive (the “Class Period”), of the important November 20, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased RCI Hospitality securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the RCI Hospitality class action, go to https://rosenlegal.com/submit-form/?case_id=44953 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants engaged in tax fraud; (2) defendants committed bribery to cover up the fact that they committed tax fraud; (3) as a result, defendants understated the legal risk facing RCI Hospitality; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the RCI Hospitality class action, go to https://rosenlegal.com/submit-form/?case_id=44953 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

BancFirst (BANF - Free Report) came out with quarterly earnings of $1.85 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $1.75 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -1.07%. A quarter ago, it was expected that this Oklahoma financial services holding company would post earnings of $1.67 per share when it actually produced earnings of $1.85, delivering a surprise of +10.78%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

BancFirst, which belongs to the Zacks Banks - Southwest industry, posted revenues of $175.48 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.20%. This compares to year-ago revenues of $163.67 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

BancFirst shares have lost about 2.1% since the beginning of the year versus the S&P 500's gain of 12.7%.

What's Next for BancFirst?While BancFirst has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for BancFirst was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.79 on $173.1 million in revenues for the coming quarter and $7.21 on $680.6 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southwest is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, GBank Financial Holdings Inc. (GBFH - Free Report) , is yet to report results for the quarter ended September 2025.

This company is expected to post quarterly earnings of $0.44 per share in its upcoming report, which represents a year-over-year change of +18.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

GBank Financial Holdings Inc.'s revenues are expected to be $19.9 million, up 23.5% from the year-ago quarter.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

TLDR

Table of Contents

TLDRLi Lin’s Ethereum Treasury Initiative Gains $1 Billion BackingNew Firm May Become Fourth-Largest Ethereum HolderEthereum Treasury Growth Offers Bullish Outlook Amid Decline

Huobi founder Li Lin is launching a $1 billion Ethereum treasury firm, backed by major Asian investors.
The planned firm will acquire and hold Ethereum as its core reserve asset to boost long-term institutional demand.
Avenir Capital has committed $200 million while Asian institutional investors have added another $500 million.
The group is in talks to acquire a Nasdaq-listed shell company to establish the Ethereum treasury firm.
This new firm could become the fourth-largest public holder of Ethereum based on its planned reserve.

Li Lin, founder of crypto exchange Huobi, plans to launch a $1 billion Ethereum treasury firm with key Asian investors. The initiative aims to acquire and hold Ethereum in large quantities, creating renewed demand amid the current downtrend. Backed by substantial institutional capital, the project is expected to have a significant impact on Ethereum holdings globally.

Li Lin’s Ethereum Treasury Initiative Gains $1 Billion Backing
Huobi founder Li Lin is establishing a $1 billion Ethereum treasury firm, backed by key investors from the crypto industry. His investment firm, Avenir Capital, committed $200 million while Asian institutions added $500 million to the fund. The firm will aim to hold Ethereum as its core reserve asset, signaling strong long-term commitment.

The group includes Fenbushi Capital co-founder Shen Bo and HashKey Group CEO Xiao Feng, both early supporters of Ethereum. According to Bloomberg, the team is acquiring a Nasdaq-listed shell company to establish the Ethereum treasury firm. A public announcement is expected to arrive within two to three weeks.

This Ethereum treasury will mirror other major firms holding ETH, joining a select group with large-scale on-chain reserves. Such firms include Tom Lee’s BitMEX and Joseph Lubin’s ConsenSys, already known for their Ethereum holdings. These strategic reserves demonstrate growing institutional belief in Ethereum’s long-term value.

New Firm May Become Fourth-Largest Ethereum Holder
Li Lin’s firm could become the fourth-largest public Ethereum holder if it secures $1 billion worth of ETH for its treasury. Current Strategic ETH Reserve data shows 70 companies hold 5.90 million ETH, or 5% of the supply. The new Ethereum treasury firm would hold more than most existing firms.

BitMine recently added $400 million in ETH, reinforcing confidence despite the market decline. BlackRock also increased its ETH position, even as other ETFs saw outflows. This steady accumulation underlines a broader strategic shift toward Ethereum treasury positioning.

Li’s initiative could reshape the Ethereum landscape by setting a new benchmark for corporate ETH holdings. The fund’s scale may influence both pricing and market sentiment. Therefore, its establishment marks a critical development in Ethereum treasury expansion.

Ethereum Treasury Growth Offers Bullish Outlook Amid Decline
The Ethereum treasury space is expanding while ETH remains below $4,000 during the current market pullback. Despite ETH’s 2% drop, institutions are increasing their Ethereum reserves. This ongoing accumulation supports confidence in Ethereum’s future potential.

Strategic Ethereum treasuries act as a hedge and long-term growth strategy for companies. With growing interest, the Ethereum treasury model is becoming a preferred option among institutional investors. Larger treasuries could stabilize ETH prices and increase liquidity.

Ethereum treasury growth signals positive momentum, despite the broader crypto market facing downward pressure. This trend could help ETH recover in the near term. Li Lin’s Ethereum treasury firm may catalyze renewed investor interest.

In an audacious move set to reshape the cryptocurrency landscape, a consortium of Asia's most influential Ethereum investors is gearing up to establish a $1 billion Ethereum treasury firm. This bold initiative, announced on October 17, 2025, aims to consolidate significant Ethereum assets under one roof, thereby enhancing liquidity and stability in the ever-volatile crypto market.

TLDR:

The Lummis Bitcoin Act could convert gold certificates into Bitcoin, injecting up to $1.5 trillion into U.S. reserves.
The Treasury may reprice gold from $42.22 to $4200 per ounce to fund Bitcoin purchases worth $90–200 billion yearly.
The Federal Reserve’s gold revaluation would create an internal cash credit for Bitcoin acquisitions without selling gold.
The plan proposes the U.S. to accumulate 200,000 BTC annually through OTC purchases for 20 years.

The proposed Lummis Bitcoin Act of 2025 could mark one of the largest financial realignments in modern U.S. history. The draft outlines how gold certificates held by the Federal Reserve could be repriced and partially converted into Bitcoin. 

Supporters say the move would strengthen national reserves while maintaining balance sheet integrity. If enacted, it would create a pathway for the Treasury to build a long-term Bitcoin position without expanding the money supply. 

The framework aims to connect legacy gold assets to a modern digital reserve model.

Treasury May Reprice Gold to Fund Bitcoin Reserves
According to MartyParty on X, the draft details how the Treasury and Federal Reserve could coordinate the conversion. 

Within 90 days of the law’s passage, the Fed would tender its existing gold certificates, currently valued at $42.22 per ounce, to the Treasury Secretary. These would then be reissued at current market rates, estimated around $4,200 per ounce as of mid-October 2025.

This revaluation would produce a cash difference of roughly $1.5 trillion on paper. Rather than selling physical gold, the Fed would internally transfer this credit to the Treasury’s general fund. The process allows the government to generate liquidity without triggering inflationary pressure or disrupting gold markets. The Treasury could then allocate between $90 and $200 billion annually toward Bitcoin accumulation.

Analysts observing the draft say this approach balances financial modernization with operational caution. It enables gradual Bitcoin exposure without abrupt policy or market shocks.

From the Lummis Bitcoin Act of 2025

Step-by-Step Process for the US to Reprice and Convert Gold Certificates to Bitcoin

Here's how it could work legally and operationally, based on the BITCOIN Act draft and related analyses:

Tender Existing Certificates: Within 90 days of…

— MartyParty (@martypartymusic) October 17, 2025

U.S. Plans Gradual Bitcoin Purchases Under New Act
The Lummis proposal reportedly sets out a controlled accumulation model. The Treasury would acquire around 200,000 Bitcoin annually through over-the-counter trades or regulated exchanges. This structure helps avoid large market swings or price distortions.

Acquired Bitcoin would be stored in secure, decentralized vaults distributed across several U.S. states. These holdings would be locked for at least two decades and could only be liquidated in declared national emergencies. The setup creates a strategic reserve similar to traditional gold storage but adapted for a digital era.

The draft suggests that such an initiative could anchor Bitcoin as a core U.S. reserve asset over time. While still in early stages, the Act represents a potential turning point for how national assets are diversified and secured.

Well-known gold bug and financial commentator Peter Schiff tweeted earlier today that Gold is more likely to reach $1 million per ounce than Bitcoin itself. He went further and predicted that a massive bear market is going to sweep the digital currency market, and traders will have to bear immense losses along the way.

Schiff is known for his pro-Gold and anti-Bitcoin views. He has been a staunch BTC critic for the better part of the last 8 years and favors precious metals, especially Gold, over the top digital currency. 

Peter Schiff Makes Bitcoin Bear Market Prediction
Schiff was on a tweeting spree earlier today as he tried to create further Fear, Uncertainty, and Doubt (FUD) around crypto following another spectacular crash. He started off with this tweet:

“Gold is more likely to hit $1 million than Bitcoin.”

“The losses that are about to hit the crypto industry will be staggering. Expect a wave of bankruptcies, defaults, and layoffs as the sector is decimated by the imminent Bitcoin and Ether crash, which will obliterate the rest of the altcoin market. There is systemic risk as well.”

Advertisement
 

And finally summing it up by posting:

“The Bitcoin bear market continues this morning, with Bitcoin now down 34% versus gold since it hit its record high in August. If you think this bear market is nearing its end, think again!”

Here is the Bitcoin/Gold price action during the last 12 months:

Image Source: TradingView
Bitcoin vs Gold Debate
The Bitcoin-Gold debate has been raging around for the better part of the last decade. Gold has been around for millennia, making its place in world economics and proving its worth. In contrast, Bitcoin is a recent challenger that has hit the ground running and is now valued at trillions of dollars on its own.

Gold, especially, was important throughout history as it was the de facto reserve currency of the world for the better part of the last 2500 years. All paper money was basically a promise to pay the equivalent amount of the yellow metal. 

However, it all ended back in 1971 when the US, led by President Richard Nixon, ended the gold standard. Gold has since witnessed considerable appreciation against the USD and other regional paper/fiat currencies and has maintained its strong position. 

Bitcoin has only had a historical presence of 16 years, but it has been essential in its own right. The digital asset is an “energy currency” that focuses on blockchain technology to deliver borderless, self-custody-based transactional capacity. Some countries now hold Bitcoin as part of their national strategic reserves, just like Gold itself, so Bitcoin is certainly catching up. 

Schiff’s Previous Hiccups
Schiff has taken Gold’s side for years and has made several damning tweets like the ones from earlier today, especially when the digital currency is on the defensive. He has been proven wrong on many occasions. 

For example, just a few years ago, he tweeted:

“Keep Dreaming. Bitcoin is never going to hit $100,000”.

The Twitterati were quick to remind him of his past hot takes that do not tend to age well. Because of the extraordinary ability and time-tested nature of both Bitcoin and Gold, the two assets are likely to have a place in the future. Bitcoin is currently the smaller of the two commodities, commanding a market cap of $2.14 trillion, while Gold has surpassed $30 trillion.